Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.45 |
| ▸ | POLD1 | P28340 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 4/20 | 0.41 |
| ▸ | TK1 | P04183 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5285299 | 0.90 | POLB (0.57) | POLBPOLA1POLD1TK1 | |
| SCHEMBL4619792 | 0.84 | DUT (0.50) | POLA1 | |
| SCHEMBL1527276 | 0.81 | TYMS (0.52) | TYMSTK1 | |
| SCHEMBL5191075 | 0.80 | POLB (0.59) | POLBPOLA1POLD1TK1 | |
| SCHEMBL8088403 | 0.79 | POLB (0.60) | POLBPOLA1POLD1TK1 | |
| SCHEMBL2148399 | 0.77 | POLB (0.67) | POLBPOLA1POLD1TYMSTK1 | |
| SCHEMBL427926 | 0.77 | POLB (0.67) | POLBPOLA1POLD1TYMSTK1 | |
| SCHEMBL15343781 | 0.77 | POLB (0.67) | POLBPOLA1POLD1TYMSTK1 | |
| SCHEMBL18790013 | 0.77 | POLB (0.67) | POLBPOLA1POLD1TYMSTK1 | |
| SCHEMBL9621370 | 0.77 | TK1 (0.67) | POLBPOLA1POLD1TYMSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725572-B1 | MACROMOLECULAR NUCLEOTIDE COMPOUNDS AND METHODS FOR USING THE SAME | AGCT GMBH (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-9035035-B2 | Macromolecular nucleotide compounds and methods for using the same | GENOVOXX GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8637650-B2 | Macromolecular nucleotide compounds and methods for using the same | GENOVOXX GMBH (DE) | 2014-01-28 | — | — | US | disclosed |
| US-20100304368-A1 | COMPONENTS AND METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS | AGCT GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100093992-A1 | Macromolecular Nucleotide Compounds and Methods for Using the Same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100029494-A1 | Macromolecular Nucleotide Compounds And Methods For Using The Same | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 2010-02-04 | — | — | US | disclosed |
| EP-2074133-A2 | COMPONENTS AND METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS | Genovoxx GmbH (DE) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008043426-A2 | COMPONENTS AND METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS | GENOVOXX GMBH (DE) | 2008-04-17 | — | — | WO | disclosed |
| EP-1725572-A2 | MACROMOLECULAR NUCLEOTIDE COMPOUNDS AND METHODS FOR USING THE SAME | Genovoxx GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005044836-A2 | MACROMOLECULAR NUCLEOTIDE COMPOUNDS AND METHODS FOR USING THE SAME | GENOVOXX GMBH (DE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093992-A1 | Macromolecular Nucleotide Compounds and Methods for Using the Same | NCL, PNP, NUDT1 | POLB 27/4885POLA1 110/4885POLD1 334/4885 |
| US-20100029494-A1 | Macromolecular Nucleotide Compounds And Methods For Using The Same | DUT, SAMHD1, PNP | POLB 26/4885POLA1 75/4885POLD1 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.